RICHLAND, WA, United States, via ETELIGIS INC., 10/29/2014 – – IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it has reached a milestone with its’ first patient, treated 10 years ago with Cesium-131. Brachytherapy utilizing Cesium-131 has since been used by over 8,300 men as their isotope of choice for treating prostate cancer.
On October 26th, 2004, Mr. Charles “Chuck” Moore became the first patient treated with the newest available implantable radioisotope utilizing Cesium-131, for the treatment of his prostate cancer. On October 27th, 2014, IsoRay Medical hosted Mr. Moore at a reception honoring his success and history as the first patient to reach ten years following Cesium-131 treatment. He is disease-free as of his recent examination with an undetectable (“zero”) PSA.
Mr. Moore told IsoRay Medical’s gathered staff that “I was told that my options were surgery, external beam radiation and the older seed therapies that were available. I was told that a new seed isotope was available, and I decided to choose Cesium-131.”
“Within a few days I was back in my RV traveling. I didn’t think much about it after that.”
Three separate studies reported recently detailed a total of 412 patients treated with Cesium-131 brachytherapy as their sole treatment for localized prostate cancer. As a group, these patients are experiencing a 96% freedom from PSA progression rate between five and six years.
These studies continue to cast light on the fact that Cesium-131 continues to live up to its billing as an ideal permanently implantable isotope for cancer treatment.
Mr. Moore’s crossing of the ten-year mark post-prostate cancer treatment with Cesium-131 builds confidence that the durability of the anti-cancer response seen now in large numbers of prostate cancer cases will continue to persist. Mr. Moore concluded with “If I had to do it all over again, I would. That’s the best testimony I can give you.”
“Maturing long term outcomes as exemplified by Mr. Moore, combined with other emerging data, demonstrate the effectiveness of Cesium-131 brachytherapy for localized prostate cancer”, said Mr. Moore’s oncologist, Dr. Leroy Korb. Dr. Korb concluded that “the fact that Mr. Moore was able to return to his traveling life-style so quickly attests to the benefits of prostate brachytherapy in general and Cesium-131 therapy specifically.”
IsoRay CEO Dwight Babcock commented, "How exciting to have the opportunity to meet Mr. Chuck Moore, IsoRay’s 1st ever patient implanted with Cesium-131. Chuck was accompanied by his daughter and granddaughter as they toured the IsoRay facilities. Chuck shared the ease of the minimally invasive procedure and how within days he returned to normal activities and resumed traveling the US. IsoRay’s Cesium-131, with its short half-life, offers rapid resolution of the acute side effects that can be associated with prostate treatment with brachytherapy. Mr. Moore is truly part of the Isoray family and has helped put us on the map within the brachytherapy world. Who would have thought that this would lead to not only caring for prostate patients but now the same Cesium-131 treatment applied to those suffering from brain, head and neck, lung, ocular and gynecological cancer? The medical community is becoming increasingly aware of the innovative alternative our Cesium-131 products offer to cancer patients.” View IsoRay Medical’s 1st Patient Celebrates Decade Cancer-Free Video.
IsoRay has recently launched a newsletter called IsoRay Happenings. Designed to communicate and share items of interest with our shareholders which may not rise to the level of a press release but show our continued progress. Our first publication speaks to our previously noted sponsored ASTRO dinners which were attended by an amazing group of industry leaders interested in hearing about the current success of Cesium-131. Institutions represented included Johns Hopkins, Memorial Sloan Kettering, Wayne State, Princeton, Yale, MD Anderson, USC and many others.
As innovative oncologists design and implement new applications for Cesium-131, IsoRay will be reporting on their novel approaches and results as they become available.
IsoRay’s various products, including Cesium-131 seeds, sutured seeds, stranded mesh and the GliaSite® radiation therapy system, give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after completion of a tumor removal or by placing seeds within the prostate. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy surrounding tissue compared to other alternative treatments. IsoRay’s cancer fighting products diminish the ability of the tumor to recur, resulting in important benefits for patients in longevity as well as quality of life.
Babcock said, "Leaders in the medical arena recognize the important need for a new powerful weapon in the battle against cancer and I believe Cesium-131 is that solution."
IsoRay is the exclusive manufacturer of Cesium-131. The pioneering brachytherapy therapy is one of the most significant advances in internal radiation therapy in 20 years. Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation).
In addition to its CMS codes, Cesium-131 is FDA-cleared and holds a CE mark for international sales in seed form for the treatment of brain cancer, prostate cancer, lung cancer, ocular melanoma cancer, colorectal cancer, gynecologic cancer, head and neck cancer and other cancers throughout the body. The treatment can be deployed using several delivery methods including single seed applicators, implantable strands and seed sutured mesh. IsoRay also sells several new implantable devices, including the GliaSite® radiation therapy system.
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of GliaSite® and Cesium-131 by visiting http://www.isoray.com. Join us on Facebook/Isoray. Follow us on Twitter @Isoray.
Safe Harbor Statement
Statements in this news release about IsoRay’s future expectations, including: the advantages of our products and their delivery systems, the experiences of our customers in recovery from prostate cancer, whether IsoRay will be able to continue to expand its base beyond prostate cancer, , whether the use of our products will increase or continue, whether awareness of our products in the medical community will continue or increase, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of past studies, patient results achieved with our products, successful completion of future research and development activities, our ability and the ability of our distributors and customers to receive and maintain all required regulatory approvals in the U.S. and internationally, continued compliance with ISO standards as audited by BSI, the success of our sales and marketing efforts, changes in reimbursement rates, changes in laws and regulations applicable to our products, and other risks detailed from time to time in IsoRay’s reports filed with the SEC.